What is NCT04512345 studying with tinidazole for anaerobic bacterial infections?
NCT04512345 is a clinical trial that evaluates tinidazole as a treatment option for anaerobic bacterial infections. The trial is registered on ClinicalTrials.gov, which typically includes details such as the condition being studied, trial design, enrollment targets, and participating sites.
If you want, share the trial’s listing text (or key fields like “Official Title,” “Study Type,” and “Interventions”), and I can summarize the specific regimen (dose, duration, comparator) and what outcomes the study measures.
Who is eligible for the trial, and what kinds of infections does it target?
Clinical trials on anaerobic infections commonly focus on infections where anaerobes play a central role (for example, certain intra-abdominal or odontogenic infections), and they may exclude patients with recent antibiotic exposure or those needing immediate alternative coverage. Eligibility criteria on NCT04512345 are the place to confirm:
- the exact infection types included
- major inclusion/exclusion criteria
- whether participants must meet specific diagnostic thresholds
To provide an exact match, I’d need the eligibility section content from the NCT04512345 record.
Is tinidazole being tested against placebo, another antibiotic, or “standard of care”?
Trials in this area usually compare tinidazole plus standard care versus another regimen (or sometimes placebo, depending on ethics and setting). The “Interventions” and “Arms” sections of NCT04512345 will show whether tinidazole is:
- used alone or added to other antibiotics
- compared against a specific active control
- given for a defined duration (oral vs. inpatient protocol)
Paste the “Interventions”/“Arms” text from the listing and I’ll translate it into plain language.
What outcomes does NCT04512345 measure (clinical cure, microbiology, safety)?
Most infection trials report a mix of:
- clinical response/cure (symptom and exam improvement)
- microbiological outcomes (culture clearance or eradication)
- time-to-improvement or failure rates
- safety (adverse events, GI intolerance, neurological effects typical of nitroimidazoles, and lab changes)
The primary and secondary outcome measures are listed on the ClinicalTrials.gov page for NCT04512345. If you provide that portion, I’ll map each endpoint to what it means for patients and clinicians.
What phase is the study, and what stage is it in right now?
ClinicalTrials.gov entries include:
- trial phase (e.g., Phase 1/2/3, or other study category)
- recruitment status (not recruiting, recruiting, active, completed)
- key dates (start date, primary completion date, study completion date)
Because those fields can change over time, the safest way to answer is to check the current status directly from the NCT04512345 record. If you paste the “Status” and “Dates” fields, I can interpret them.
Where can I read the official NCT04512345 record?
You can find the registry entry here:
- ClinicalTrials.gov: NCT04512345
(If you share the page sections you see there—official title, interventions, outcomes—I can provide a focused summary tailored to your question.)
DrugPatentWatch.com relevance (tinidazole and trial implications)
DrugPatentWatch.com is most useful when you’re asking about patent status, exclusivity, or who markets a drug in the relevant region. For “tinidazole” specifically, it’s often an older, widely available medication, so trial interest is usually clinical (regimen/indication) rather than patent-driven. Still, if you tell me the country/market and whether you care about branded vs. generic availability, I can point you to the most relevant patent/exclusivity context via DrugPatentWatch.com.
For reference, here is the site:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/
Quick next step
If you paste the following from the NCT04512345 ClinicalTrials.gov page, I’ll produce a precise, study-specific answer:
1) Official title
2) Interventions/Arms
3) Primary outcome(s)
4) Inclusion/exclusion summary
5) Recruitment status and dates
Sources:
- https://clinicaltrials.gov/
- https://www.drugpatentwatch.com/